|
HK1245154A1
(zh)
|
2014-12-30 |
2018-08-24 |
细胞基因公司 |
抗cd47抗体及其用途
|
|
US9650441B2
(en)
|
2015-09-21 |
2017-05-16 |
Erasmus University Medical Center |
Anti-CD47 antibodies and methods of use
|
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
|
JP7120989B2
(ja)
*
|
2016-07-06 |
2022-08-17 |
セルジーン コーポレイション |
低免疫原性を有する抗体及びその使用
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｃｄ４７併用療法
|
|
US20200140565A1
(en)
|
2016-10-20 |
2020-05-07 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
CA3042581A1
(en)
*
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
WO2018081898A1
(en)
*
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
US20190309066A1
(en)
*
|
2017-03-22 |
2019-10-10 |
Arch Oncology, Inc. |
Combination therapy for the treatment of solid and hematological cancers
|
|
EP3601351A1
(en)
*
|
2017-03-27 |
2020-02-05 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
CN119285787A
(zh)
|
2017-03-31 |
2025-01-10 |
健玛保控股有限公司 |
双特异性抗cd37抗体、单克隆抗cd37抗体及其使用方法
|
|
BR112019021520A2
(pt)
|
2017-04-14 |
2020-08-04 |
Tollnine, Inc. |
oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
|
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
|
CN109096395B
(zh)
*
|
2017-06-20 |
2022-06-24 |
华兰生物工程股份有限公司 |
阻断型cd47纳米抗体及其用途
|
|
ES2976558T3
(es)
|
2017-06-21 |
2024-08-05 |
The Board Of Trustees Of The Leland Stanfordjunior Univ |
Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas
|
|
WO2019022600A1
(en)
*
|
2017-07-24 |
2019-01-31 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47
|
|
MX2020001309A
(es)
*
|
2017-08-02 |
2020-08-20 |
Phanes Therapeutics Inc |
Anticuerpos anti-cd47 y sus usos.
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
CN108503708B
(zh)
*
|
2017-09-01 |
2021-07-30 |
北京智仁美博生物科技有限公司 |
抗人cd47抗体及其用途
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
KR102366853B1
(ko)
*
|
2017-11-10 |
2022-02-23 |
아이-맵 바이오파마 유에스 리미티드 |
Cd47 항체 및 사이토카인을 포함하는 융합 단백질
|
|
AR113862A1
(es)
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
BR112020014202A2
(pt)
|
2018-01-12 |
2020-12-01 |
Aurigene Discovery Technologies Limited |
compostos de 1,2,4-oxadiazol como inibidores de vias de sinalização cd47
|
|
EP3765090A4
(en)
*
|
2018-03-13 |
2022-03-16 |
Trillium Therapeutics Inc. |
COMBINATION OF CD47 BLOCKADE THERAPY AND A CD38 ANTIBODY
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110305212A
(zh)
*
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
WO2019200357A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
CN112566662A
(zh)
*
|
2018-06-15 |
2021-03-26 |
阿库鲁斯生物科学公司 |
针对cd47的阻断抗体及其使用方法
|
|
WO2020009725A1
(en)
*
|
2018-07-05 |
2020-01-09 |
Trican Biotechnology Co., Ltd |
Human anti-cd47 antibodies and uses thereof
|
|
KR102587442B1
(ko)
|
2018-08-31 |
2023-10-11 |
난징 산홈 팔마세우티칼 컴퍼니 리미티드 |
항-cd47 항체 또는 그 적용
|
|
EP3860609A4
(en)
*
|
2018-10-01 |
2022-08-03 |
Secura Bio, Inc. |
COMBINATION THERAPIES
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
GB2596411B
(en)
*
|
2018-10-29 |
2023-09-20 |
Tigatx Inc |
Compositions and methods comprising IgA antibody constructs
|
|
GB2593632B8
(en)
|
2018-10-29 |
2026-07-08 |
Umc Utrecht Holding Bv |
IGA mediated killing of aberrant cells by CD47-Sirpalpha checkpoint inhibition of neutrophils
|
|
AU2019375193A1
(en)
|
2018-11-08 |
2021-05-13 |
Aurigene Oncology Limited |
Combination of small molecule CD-47 inhibitors with other anti-cancer agents
|
|
CN109224079B
(zh)
*
|
2018-11-26 |
2020-08-04 |
中国药科大学 |
Dna甲基转移酶抑制剂与抗cd47抗体联合用于制备抗肿瘤药物的医药用途
|
|
JP2022521624A
(ja)
*
|
2019-02-26 |
2022-04-11 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
抗ｃｄ４７抗体を含む製剤、その調製方法および使用
|
|
TW202104260A
(zh)
|
2019-04-05 |
2021-02-01 |
美商西建公司 |
腫瘤選擇性結合ｃｄ４７之抗體之工程
|
|
EP3955963A4
(en)
*
|
2019-04-18 |
2023-05-31 |
QLSF Biotherapeutics Inc. |
ANTIBODIES TARGETED TO HUMAN CD47
|
|
EP3980747A1
(en)
|
2019-06-07 |
2022-04-13 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
|
CN112206320B
(zh)
*
|
2019-07-12 |
2025-02-25 |
鲁南制药集团股份有限公司 |
一种cd47单克隆抗体冻干粉制剂及其制备工艺
|
|
AU2020315598B2
(en)
|
2019-07-16 |
2024-12-12 |
Gilead Sciences, Inc. |
HIV vaccines and methods of making and using
|
|
JP7808546B2
(ja)
|
2019-09-03 |
2026-01-29 |
中山康方生物医▲藥▼有限公司 |
抗ｃｄ４７モノクローナル抗体及びその使用
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
WO2021080920A2
(en)
*
|
2019-10-23 |
2021-04-29 |
Arch Oncology, Inc. |
Combination therapy for the treatment of solid and hematological cancers
|
|
JP7520972B2
(ja)
*
|
2019-10-25 |
2024-07-23 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｃｄ４７抗体及びその使用
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
WO2021113596A2
(en)
*
|
2019-12-05 |
2021-06-10 |
Sorrento Therapeutics, Inc. |
Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
|
|
JP2023507432A
(ja)
|
2019-12-20 |
2023-02-22 |
インスティル バイオ （ユーケイ） リミテッド |
腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
|
|
CN115362003B
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
CN114929749A
(zh)
*
|
2020-01-09 |
2022-08-19 |
信达生物制药(苏州)有限公司 |
抗cd47抗体和抗cd20抗体的组合在制备用于预防或治疗肿瘤的药物中的应用
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2021174021A1
(en)
*
|
2020-02-27 |
2021-09-02 |
Fred Hutchinson Cancer Research Center |
Tunable extended release hydrogels
|
|
IL295759A
(en)
|
2020-02-28 |
2022-10-01 |
Tallac Therapeutics Inc |
Transglutaminase mediated coupling
|
|
CN111454359B
(zh)
*
|
2020-03-23 |
2021-06-29 |
倍而达药业（苏州）有限公司 |
Cd47抗体或其免疫活性片段及应用
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
TWI869582B
(zh)
*
|
2020-04-10 |
2025-01-11 |
大陸商和記黃埔醫藥（上海）有限公司 |
抗ｃｄ４７抗體及其用途
|
|
CN119708235A
(zh)
*
|
2020-04-17 |
2025-03-28 |
鲁南制药集团股份有限公司 |
抗cd47单克隆抗体
|
|
US20230140868A1
(en)
*
|
2020-04-23 |
2023-05-11 |
Alpha Beta Holdings, Llc |
Compositions and methods for treating cancer
|
|
EP4168449A1
(en)
*
|
2020-06-22 |
2023-04-26 |
MorphoSys AG |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
|
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
WO2022007947A1
(zh)
*
|
2020-07-10 |
2022-01-13 |
信达生物制药(苏州)有限公司 |
抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
|
|
CA3192465A1
(en)
*
|
2020-09-18 |
2022-03-24 |
Laure Bouchez |
Cd47-cd38 bispecific antibodies
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
WO2022140659A2
(en)
|
2020-12-23 |
2022-06-30 |
D-10 Therapeutics, Inc. |
Anti-cd47 antibodies and uses thereof
|
|
JP2024503822A
(ja)
*
|
2021-01-05 |
2024-01-29 |
ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン |
Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
|
|
WO2022190058A1
(en)
|
2021-03-12 |
2022-09-15 |
Dcprime B.V. |
Methods of vaccination and use of cd47 blockade
|
|
US20240190993A1
(en)
|
2021-04-14 |
2024-06-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
KR102757524B1
(ko)
*
|
2021-06-30 |
2025-01-21 |
(주)이노베이션바이오 |
Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
CA3229503A1
(en)
*
|
2021-08-25 |
2023-03-02 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition containing fusion protein
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
KR20240162568A
(ko)
*
|
2022-03-25 |
2024-11-15 |
우시 바이올로직스 아일랜드 리미티드 |
항-her2/항-cd47 분자 및 이의 용도
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024121311A1
(en)
*
|
2022-12-07 |
2024-06-13 |
Ichnos Sciences SA |
Cd47/cd38 bispecific antibodies and methods of use to treat leukemia
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260217851A1
(en)
*
|
2022-12-22 |
2026-07-30 |
The Medical College Of Wisconsin, Inc. |
Compositions that Target CD138 and CD3 and Methods of Making and Using the Same
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａｓ調節化合物
|
|
EP4746909A2
(en)
*
|
2023-07-21 |
2026-05-27 |
The Board of Trustees of the Leland Stanford Junior University |
MODULATION OF MYELOID FCgamma RECEPTOR DEPLETION
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|